At Aesthetics 360, our team of experienced professionals is dedicated to providing safe, effective, and customized weight loss solutions tailored to your unique needs
7 AG1 Alternatives to Consider in 2026
3-Adrenergic Receptor Modulation Both hGH and AOD9604 increase 3-adrenergic receptor (3-AR) expression in adipose tissue importantly, restoring repressed 3-AR RNA levels in obese mice to levels comparable with those in lean mice
Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 s selective action and why this selectivity matters for safe, targeted fat metabolism
Researchers working with tiny target masses often prefer this
It is highly stable, which is one reason compounding pharmacies prefer it
